← All trials
NCT07024589
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 4, 2025
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Jun 17, 2025
- Last posted
- Sep 11, 2025
- Enrollment
- 64
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AN2 Therapeutics, IncLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.